Welcome to our dedicated page for Oncotelic Therapeutics news (Ticker: OTLC), a resource for investors and traders seeking the latest updates and insights on Oncotelic Therapeutics stock.
Oncotelic Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company focused on oncology, immunotherapy and rare-disease therapeutics. Company updates cover its internal drug pipeline, orphan oncology programs, antisense and small molecule injectable drug candidates, and partnerships or joint ventures used to license and co-develop selected candidates.
Recurring OTLC news also includes the PDAOAI AI platform for research, biomarker discovery, regulatory processes and GMP-compliant robotics, the company's 45% interest in GMP Bio and related Sapu Bio and Sapu Nano programs, and completed portfolio actions such as field-specific monetization of N2B nose-to-brain delivery assets.
Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Nano announced a peer-reviewed Biomedicines publication detailing the preclinical translational package for Sapu003, an intravenous Deciparticle™ formulation of everolimus. The study covers ADME, pharmacokinetics, tissue distribution, metabolism, excretion, GLP repeat-dose toxicology, cGMP manufacturing, release testing, and product stability.
The data show Deciparticle™ technology enabled a clinically manufacturable IV everolimus while maintaining intrinsic metabolic characteristics and reducing gastrointestinal exposure versus oral everolimus, with no treatment-related gastric pathology in GLP studies. According to Oncotelic, the work supports the ongoing Phase 1b trial SP-03-B101 in advanced mTOR-sensitive solid tumors and demonstrates reproducible cGMP manufacturing, which the company views as strong validation of the Deciparticle™ platform.
Oncotelic (OTCQB:OTLC)/b) and its 45%-owned subsidiary Sapu Nano completed the initial safety cohort of the Phase 1b trial of Sapu003, an intravenous everolimus formulation. The Safety Review Committee observed no dose-limiting toxicities and recommended escalation to the next dose level.
The company has begun expanding the trial into Europe to add sites and accelerate enrollment. A recent peer-reviewed publication details the Deciparticle™ nanoparticle platform, highlighting scalable cGMP manufacturing, stability, compatibility with multiple hydrophobic drugs, and preclinical antitumor activity supporting Sapu003’s clinical development.
Oncotelic (OTCQB: OTLC) and Sapu Nano reported peer-reviewed validation of their Deciparticle™ nanoparticle platform through development of Sapu003, an intravenous everolimus formulation.
The International Journal of Molecular Sciences paper describes formulation design, scalable cGMP manufacturing, stability, preclinical antitumor activity, and supports the ongoing Phase 1b trial in advanced mTOR-sensitive solid tumors with weekly IV Sapu003 plus exemestane.
Oncotelic (OTCQB: OTLC) launched an AI-powered GMP manufacturing services platform at BIO International Convention 2026 in San Diego. The Platform combines the PDAOAI™ AI system, digital batch records, and intelligent robotics via a collaboration with TechForce Robotics to support modern pharmaceutical manufacturing.
The Platform targets pharma, biotech, CDMOs, and advanced therapy developers by enabling electronic batch records, GMP workflow digitization, quality support, process monitoring, and robotic integration. Oncotelic is also showcasing its Deciparticle™ nanomedicine platform, including SAPU003 in a Phase 1b clinical study.
Oncotelic Therapeutics (OTCQB: OTLC) announced completion of key Phase 2 objectives in its AI-powered GMP manufacturing automation initiative with TechForce Robotics at SAPU Bio, its 45%-owned OEB-5 sterile injectable cGMP joint venture.
The PDAOAI™ platform now supports sterile operations, eBR, GMP workflows, cleanroom monitoring, and autonomous materials movement, and will be showcased at BIO International Convention 2026.
Oncotelic (OTC:OTLC) will showcase its PDAOAI™ drug discovery platform in the Product & Engineering keynote at Qdrant Vector Space Day 2026 on June 11 in San Francisco.
According to Oncotelic, PDAOAI indexes about 28 million PubMed abstracts on Qdrant and incorporates novel manifold folding and shell sampling techniques to enhance biomedical knowledge retrieval and reduce LLM hallucinations.
The company reports compressing development of SAPU 003 and SAPU 006 from concept to IND within 24 months, including GMP manufacturing build-out and first-in-human clinical material shipment.
Oncotelic Therapeutics (OTCQB: OTLC) was featured in a BioMedWire editorial highlighting nanotechnology-based oncology drug delivery. The company is developing Sapu003 and its Deciparticle platform, focusing on nanotech-driven delivery systems and pharmacokinetic optimization to enhance existing cancer therapies rather than discovering entirely new compounds.
Oncotelic Therapeutics (OTCQB:OTLC) and Sapu Nano are expanding the Phase 1b Sapu003 (Everolimus for Injection) program and have appointed Global Clinical Trials (GCT) as lead CRO for multinational Study SP-03-B101.
The move extends development beyond Australia into Europe, builds global clinical infrastructure, and supports future Phase 3 and registrational plans using the Deciparticle™ nanomedicine platform.
Oncotelic Therapeutics (OTCQB: OTLC) was featured in a BioMedWire editorial highlighting industry efforts to enhance existing cancer therapies through advanced drug delivery.
The company is progressing its Sapu003 program and Deciparticle(TM) platform, targeting scalable nanotechnology-enabled delivery and AI-enhanced biomedical infrastructure for oncology and rare disease applications.
Oncotelic Therapeutics (OTCQX:OTLC) and Sapu Nano will present the Deciparticle™ nanomedicine platform at BIO International Convention 2026 in San Diego.
The company will showcase ultra-small intravenous nanomedicine formulations, AI-enabled oncology development via PDAOAI™, and progress in programs including Sapu006 and Sapu003.